Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Our approach prioritizes high-impact genetic medicine candidates for cardiovascular diseases and APOE4-associated Alzheimer’s disease. By leveraging early proof-of-concept data, we are committed to efficient development and advanced manufacturing to address the underlying genetic causes of devastating diseases.
Our pipeline includes investigational AAV-mediated gene therapies in both cardiovascular conditions and conditions of the central nervous system (CNS). We aim to create substantial positive impacts and reduce the burdens placed on patients and healthcare systems. Lexeo's management team comprises pioneers and driven leaders with decades of experience in gene therapy and rare diseases. We remain focused on employing strategic partnerships and collaborations to push the boundaries of gene therapy and offer potential cures for complex genetic disorders. With an FDA-granted Fast Track designation for our therapies, we are poised to advance clinical trials that could change the lives of the patients we serve.
United States only